abrdn plc Acquires New Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

abrdn plc acquired a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) during the 4th quarter, HoldingsChannel reports. The institutional investor acquired 504,528 shares of the biotechnology company’s stock, valued at approximately $3,022,000.

Several other institutional investors also recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. increased its holdings in BioCryst Pharmaceuticals by 96.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 4,865 shares of the biotechnology company’s stock valued at $34,000 after buying an additional 2,388 shares during the period. Teacher Retirement System of Texas increased its holdings in BioCryst Pharmaceuticals by 4.9% during the third quarter. Teacher Retirement System of Texas now owns 53,640 shares of the biotechnology company’s stock valued at $380,000 after buying an additional 2,519 shares during the period. Fifth Third Bancorp increased its holdings in BioCryst Pharmaceuticals by 17,500.0% during the third quarter. Fifth Third Bancorp now owns 3,520 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 3,500 shares during the period. Teza Capital Management LLC increased its holdings in BioCryst Pharmaceuticals by 12.8% during the third quarter. Teza Capital Management LLC now owns 36,904 shares of the biotechnology company’s stock valued at $261,000 after buying an additional 4,180 shares during the period. Finally, Great Valley Advisor Group Inc. increased its holdings in BioCryst Pharmaceuticals by 34.7% during the third quarter. Great Valley Advisor Group Inc. now owns 16,300 shares of the biotechnology company’s stock valued at $115,000 after buying an additional 4,200 shares during the period. 85.88% of the stock is owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Stock Performance

NASDAQ BCRX opened at $4.16 on Monday. The firm’s fifty day simple moving average is $5.07 and its two-hundred day simple moving average is $5.52. BioCryst Pharmaceuticals, Inc. has a 12-month low of $4.03 and a 12-month high of $9.06. The firm has a market capitalization of $857.58 million, a P/E ratio of -3.53 and a beta of 1.90.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Monday, February 26th. The biotechnology company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.04). The firm had revenue of $93.40 million for the quarter, compared to analyst estimates of $89.19 million. As a group, sell-side analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.69 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Needham & Company LLC reissued a “buy” rating and set a $12.00 price objective on shares of BioCryst Pharmaceuticals in a report on Wednesday, April 10th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $13.83.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.